Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class .
NovadiscoveryFebruary 16, 2021 GMT
NOVA to develop COVID-19 disease model to support Sanofi’s vaccine and therapeutic efforts
Lyon, France – 16 February 2021: Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised €2.5 million in a Series A2 financing round from Sanofi.
The funds will be used to advance NOVA’s
in silico clinical trial simulation platform, JINKO; to facilitate the Company’s expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi. JINKO’s workflows are designed to closely resemble those of real life clinical studies and it offers an integrated suite of applications
iTeos to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Nachrichtenquelle: globenewswire | 17.02.2021, 13:00 | 126 | 0 CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will host a fireside chat at the virtual 10
th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 3:00 p.m. ET. A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approx
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Investegate |Silence Therapeutics Announcements | Silence Therapeutics: First dosing for SLN360 investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.